NCT05097794 - "A Clinical Trial to Evaluate Drug-drug Interactions and Safety Between BR1015-1 and BR1015-2 in Healthy Volunteers" | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 16, 2021

Primary Completion Date

October 22, 2021

Study Completion Date

October 22, 2021

Conditions

Hypertension

Interventions

DRUG

BR1015-1

\- Administration to the BR1015-1 group: 60 mg of BR1015-1 will be administered one tablet once a day, five-day repeated doses.

DRUG

BR1015-2

\- Administration to the BR1015-2 group: 1.5 mg of BR1015-2 will be administered one tablet once a day, five-day repeated doses.

DRUG

BR1015-1 + BR1015-2

\- Co-administration to the BR1015-1+BR1015-2 group: 60 mg of BR1015-1 one tablet and 1.5 mg of BR1015-2 one tablet will be co-administered once a day, five-day repeated doses.

Trial Locations (1)

13520

CHA Bundang Medical Center, CHA University, Gyeonggi-do